Search

Search Constraints

You searched for: Author/Creator Lynch, Mark

Search Results

2. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. (October 2017)

4. CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. (4th June 2018)

7. Elotuzumab in combination with thalidomide and low‐dose dexamethasone: a phase 2 single‐arm safety study in patients with relapsed/refractory multiple myeloma. (19th July 2016)

8. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. (29th May 2018)